Repligen Announces Acquisition of BioLife Solutions in $11.25 Per Share Cash and Stock Deal

Merger Structure and Regulatory Approvals

The acquisition will be executed through a two-step merger. Initially, Repligen’s wholly owned subsidiary, Bravo Merger Sub I, Inc., will merge into BioLife, which will survive as a direct Repligen subsidiary. Subsequently, BioLife will merge into another Repligen subsidiary, Bravo Merger Sub II, LLC, which will survive as a direct Repligen subsidiary. This two-step approach facilitates efficient integration.

Completion depends on satisfying conditions such as expiration or termination of the Hart-Scott-Rodino Antitrust waiting period and obtaining required antitrust consents in specified jurisdictions. Additionally, Repligen’s common stock issuance must receive Nasdaq listing approval, and the SEC must declare effective the Registration Statement on Form S-4 filed by Repligen.

Details on Merger Consideration and Stock Issuance

Each outstanding BioLife common share (excluding treasury shares, shares held by Repligen or subsidiaries, and shares subject to appraisal rights) will convert into $11.25 cash plus 0.1442 fully paid Repligen common shares. Fractional Repligen shares will not be issued; instead, cash will be paid in lieu. Cash consideration will be paid without interest at the effective time of the first merger.

Equity awards of BioLife will convert automatically into merger consideration at the first merger’s effective time. Fractional share entitlements to stockholders will be settled in cash, streamlining post-closing settlements.

Acceleration and Settlement of BioLife Equity Awards

The merger agreement accelerates vesting of BioLife equity awards immediately before the first merger. All BioLife stock options, vested or unvested, will fully vest and be cancelled in exchange for cash payments calculated as the number of option shares minus the aggregate exercise price, net of tax withholdings.

Time-based restricted stock units (RSUs) will fully vest and be settled in BioLife common stock, net of taxes. Performance-based restricted stock units (PSUs) will vest fully based on the greater of target or actual performance as of the latest practicable date before the merger, also net of taxes. Unvested restricted stock awards (RSAs) will also fully vest and be released in shares, net of applicable tax withholdings.

Board Approvals and Stockholder Vote Requirement

Both Repligen and BioLife boards have approved the merger agreement and related transactions. The merger’s completion is contingent upon approval by a majority of BioLife’s outstanding common stockholders voting at a duly convened meeting. BioLife will hold a stockholders’ meeting to obtain this approval. While no date has been set or management recommendations disclosed, board endorsements indicate leadership alignment.

The agreement includes standard representations, warranties, and covenants. BioLife has committed to operate its business in the ordinary course and maintain its business organization and assets, subject to exceptions and Repligen’s written consent. Repligen has made similar commitments for the period between signing and closing.

Anticipated Closing Timeline and Conditions

The transaction is expected to close in the fourth quarter of 2026, contingent on customary closing conditions. The filing does not specify total transaction or enterprise value. The timeline suggests an expedited process if regulatory and stockholder approvals proceed smoothly, though timing may be impacted by regulatory reviews and voting procedures.

Closing conditions include absence of any law or order prohibiting the merger, accuracy of representations and warranties, and no continuing material adverse effect on either party. These conditions protect both companies if material changes occur before closing.

Public Disclosure and Regulatory Filings

The filing was made under Securities Act Rule 425, allowing pre-registration written communications about the proposed combination. Repligen will file a Registration Statement on Form S-4 containing the proxy statement and prospectus, which the SEC must declare effective before closing.

This disclosure process ensures all stockholders receive comprehensive information about the transaction’s terms and risks. BioLife stockholders will use the proxy statement to make an informed vote, while Repligen shareholders will learn about ownership changes due to new share issuance.

Antitrust and Securities Compliance Considerations

Besides the Hart-Scott-Rodino waiting period, the parties must secure antitrust approvals in specified jurisdictions, potentially including international markets. Both companies will use best efforts to satisfy conditions and complete the merger.

Nasdaq listing approval for Repligen shares issued in the merger and SEC effectiveness of the Form S-4 registration statement are required preconditions, ensuring compliance with securities laws.

Impact on Repligen Shareholders and Capital Structure

The deal will dilute existing Repligen shareholders as new shares are issued to BioLife shareholders. The filing does not disclose BioLife’s outstanding shares, so dilution magnitude is unknown. Repligen shareholders should review the forthcoming proxy statement for detailed ownership and financial impacts.

The cash portion ($11.25 per BioLife share) requires Repligen to maintain liquidity or secure financing. The filing omits details on total purchase price, funding sources, or financing arrangements. Investors should monitor future disclosures and earnings for funding updates.

Material Adverse Effect Clause and Business Operations

A key closing condition is no continuing material adverse effect on either company, allowing termination if significant negative changes occur. The merger agreement defines material adverse effect scope, though specifics are not disclosed here. Both companies will operate in the ordinary course between signing and closing.

BioLife and Repligen are restricted from taking certain actions without each other’s written consent to preserve transaction value and prevent detrimental conduct. The filing notes a detailed list of prohibited actions exists but does not specify them.